Rhumbline Advisers increased its position in shares of Chemed Co. (NYSE:CHE) by 7.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,149 shares of the company’s stock after purchasing an additional 3,656 shares during the period. Rhumbline Advisers’ holdings in Chemed were worth $13,159,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CHE. JPMorgan Chase & Co. raised its holdings in Chemed by 111.5% during the third quarter. JPMorgan Chase & Co. now owns 182,551 shares of the company’s stock worth $36,125,000 after purchasing an additional 96,237 shares in the last quarter. Old Mutual Global Investors UK Ltd. raised its holdings in Chemed by 173.5% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 95,212 shares of the company’s stock worth $19,237,000 after purchasing an additional 60,399 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Chemed during the fourth quarter worth about $9,296,000. APG Asset Management N.V. purchased a new position in Chemed during the third quarter worth about $5,657,000. Finally, Arizona State Retirement System raised its holdings in Chemed by 224.3% during the fourth quarter. Arizona State Retirement System now owns 26,835 shares of the company’s stock worth $6,521,000 after purchasing an additional 18,561 shares in the last quarter. 96.16% of the stock is owned by hedge funds and other institutional investors.
In other Chemed news, VP Naomi C. Dallob sold 1,050 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $257.00, for a total value of $269,850.00. Following the completion of the transaction, the vice president now directly owns 6,649 shares of the company’s stock, valued at $1,708,793. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Michael D. Witzeman sold 1,000 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $250.00, for a total transaction of $250,000.00. Following the completion of the transaction, the vice president now directly owns 3,334 shares of the company’s stock, valued at $833,500. The disclosure for this sale can be found here. Company insiders own 4.90% of the company’s stock.
Chemed (NYSE:CHE) last issued its earnings results on Wednesday, February 14th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.05. Chemed had a net margin of 5.89% and a return on equity of 30.04%. The company had revenue of $428.35 million during the quarter, compared to analysts’ expectations of $423.83 million. During the same period last year, the company posted $2.10 earnings per share. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year.
The business also recently announced a quarterly dividend, which will be paid on Monday, March 19th. Shareholders of record on Monday, February 26th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a yield of 0.42%. Chemed’s dividend payout ratio (DPR) is presently 19.28%.
CHE has been the subject of several analyst reports. Royal Bank of Canada increased their price target on shares of Chemed to $232.00 and gave the stock a “sector perform” rating in a report on Tuesday, October 31st. Zacks Investment Research raised shares of Chemed from a “hold” rating to a “buy” rating and set a $251.00 price target for the company in a report on Thursday, November 2nd. ValuEngine cut shares of Chemed from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Oppenheimer increased their price target on shares of Chemed from $270.00 to $275.00 and gave the stock an “outperform” rating in a report on Friday, February 16th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Chemed presently has an average rating of “Hold” and a consensus price target of $261.33.
COPYRIGHT VIOLATION WARNING: “Rhumbline Advisers Has $13.16 Million Position in Chemed Co. (CHE)” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3227711/rhumbline-advisers-has-13-16-million-position-in-chemed-co-che.html.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.